Sandoz announced that it has completed its USD 1.3 billion acquisition of EBEWE Pharma's specialty generic injectables business, paving the way for the creation of a global center of excellence in generic oncology injectables. "We are delighted to combine EBEWE Pharma's portfolio and pipel ... more
To use all functions of this page, please activate cookies in your browser.
